Pharmacological profiling of a berbamine derivative for lymphoma treatment
Open Access
- 10 January 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (2) , 309-323
Abstract
Ca2+/calmodulin-dependent protein kinase II γ (CAMKIIγ) has been identified as a potential target for treating cancer. Based on our previous study of berbamine (BBM) as a CAMKIIγ inhibitor, we have synthesized a new BBM derivative termed PA4. Compared with BBM, PA4 showed improved potency and specificity and was more cytotoxic against lymphoma and leukemia than against other types of cancer. In addition to indirectly targeting c-Myc protein stability, we demonstrated that its cytotoxic effects were also mediated via increased reactive oxygen species production in lymphoma cells. PA4 significantly impeded tumor growth in vivo in a xenograft T-cell lymphoma mouse model. Pharmacokinetics studies demonstrated quick absorption into plasma after oral administration, with a maximum concentration of 1680 ± 479 ng/mL at 5.33 ± 2.31 hours. The calculated oral absolute bioavailability was 34.1%. Toxicity assessment of PA4 showed that the therapeutic window used in our experiments was safe for future development. Given its efficacy, safety, and favorable pharmacokinetic profile, PA4 is a potential lead candidate for treating lymphoma.Keywords
This publication has 47 references indexed in Scilit:
- Functional genomics identifies therapeutic targets for MYC-driven cancerProceedings of the National Academy of Sciences, 2012
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Siva1 suppresses epithelial–mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubulesProceedings of the National Academy of Sciences, 2011
- Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and IICell Cycle, 2011
- Activated Ca2+/Calmodulin-Dependent Protein Kinase IIγ Is a Critical Regulator of Myeloid Leukemia Cell ProliferationCancer Research, 2008
- Pyrimidine-based inhibitors of CaMKIIδBioorganic & Medicinal Chemistry Letters, 2008
- α-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progressionLaboratory Investigation, 2007
- Structure of the Autoinhibited Kinase Domain of CaMKII and SAXS Analysis of the HoloenzymeCell, 2005
- CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulumGenes & Development, 2004
- The newly synthesized selective Ca2+calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cellsBiochemical and Biophysical Research Communications, 1991